Investigating the Potential of High Permeation Vesicle-Based Methotrexate Gel for Localized Therapy in Rheumatoid Arthritis
Pharmaceutical Research · 2026
DOI: 10.1007/s11095-026-04070-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Keshav Kumar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Na…. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Methotrexate (MTX) is a clinically approved, potent disease-modifying antirheumatic drug used to manage rheumatoid arthritis. However, its systemic administration is associated with severe toxicity and bioavailability challenges. Localized MTX therapy holds significant potential by enabling site-specific action while diminishing the risk of systemic toxicity. METHODS: In this study, we investigated the therapeutic potential of systematically designed methotrexate-loaded high permeation vesicles (MTX-HPVs) in rheumatoid arthritis. HPVs comprise biocompatible phospholipids and a synergistic combination of permeation enhancers optimized using a quality-by-design approach. The thin-film hydration technique was used to formulate MTX-HPVs. Furthermore, MTX-HPVs were integrated into the Carbopol® 934P NF gelling matrix for ease of application and prolonged retention. RESULTS: The optimized MTX-HPVs exhibited optimal quality attributes with a sustained-release pattern for up to 48 h. Morphological assessment revealed a spherical shape of MTX-HPVs. The prepared MTX-HPVs loaded gel displayed enhanced flux (~ 6.9-fold) and permeation (~ 3.5-fold) compared to the free MTX gel. Furthermore, increased cellular internalization and reduced IC50 (0.57 ± 0.03 µg/mL) of the formulation in macrophage cells indicated the improved therapeutic potential of HPV-based therapy. In vivo studies revealed that MTX-HPVs gel significantly reduced inflammation and exhibited superior safety compared to free MTX gel. Radiographic imaging corroborated the enhanced efficacy and joint-restorative action of this formulation. CONCLUSION: The MTX-HPVs gel substantially enhanced the therapeutic efficacy of MTX, demonstrating HPVs as a promising carrier system for localized methotrexate therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Sector 67, Punjab, 160062, India.
- Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Sector 67, Punjab, 160062, India. sanyogjain@niper.ac.in.
Zitieren
APA
Kumar, K., Akhtar, J., Dighe, S., Yadav, V., Ansari, M. M., & Jain, S. (2026). Investigating the Potential of High Permeation Vesicle-Based Methotrexate Gel for Localized Therapy in Rheumatoid Arthritis. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04070-y
Vancouver
Kumar K, Akhtar J, Dighe S, Yadav V, Ansari MM, Jain S. Investigating the Potential of High Permeation Vesicle-Based Methotrexate Gel for Localized Therapy in Rheumatoid Arthritis. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04070-y
BibTeX
@article{Kumar2026,
author = {Kumar, Keshav and Akhtar, Junia and Dighe, Sayali and Yadav, Vivek and Ansari, Md Meraj and Jain, Sanyog},
title = {Investigating the Potential of High Permeation Vesicle-Based Methotrexate Gel for Localized Therapy in Rheumatoid Arthritis},
journal = {Pharmaceutical Research},
year = {2026},
doi = {10.1007/s11095-026-04070-y}
}
EUVIMED